MLICM
ORIC icon

Metropolitan Life Insurance Company (MetLife)’s Oric Pharmaceuticals ORIC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,149
Closed -$29.5K – 1482
2024
Q1 		$29.5K Hold
2,149
– – ﹤0.01% 1669
2023
Q4 		$19.8K Hold
2,149
– – ﹤0.01% 1930
2023
Q3 		$13K Hold
2,149
– – ﹤0.01% 2097
2023
Q2 		$16.7K Buy
+2,149
New +$12.2K ﹤0.01% 2029
2022
Q1 		– Sell
-8,707
Closed -$128K – 2556
2021
Q4 		$128K Buy
8,707
+161
+2% +$2.51K ﹤0.01% 2331
2021
Q3 		$179K Buy
8,546
+1,254
+17% +$25.4K ﹤0.01% 2164
2021
Q2 		$129K Buy
7,292
+688
+10% +$15.1K ﹤0.01% 2453
2021
Q1 		$162K Hold
6,604
– – ﹤0.01% 2162
2020
Q4 		$224K Buy
+6,604
New +$189K ﹤0.01% 1866
2020
Q3 		– Sell
-3,187
Closed -$107K – 2585
2020
Q2 		$107K Buy
+3,187
New +$102K ﹤0.01% 2216

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ORIC Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Oric Pharmaceuticals (ORIC) in Q2 2024, closing a stake of 2,149 shares — an estimated $29.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ORIC in Q2 2020 and held it in 10 quarters. The position peaked at $224K in Q4 2020. 112 funds tracked by Wall St. Rank hold ORIC as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Oric Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,149 Oric Pharmaceuticals shares in Q2 2024, an estimated $29.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 10 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Oric Pharmaceuticals position peaked at $224K in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.